Skip to main content
logo
Avalo Therapeutics, Inc. (AVTX)
NASDAQ: AVTX · Real-Time Price · USD
18.05
-0.20 (-1.10%)
Aug 3, 2026, 4:00 PM EDT - Market closed

Avalo Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
-0.060.441.9218.055.4
Revenue Growth
--86.62%-77.08%-89.34%234.40%-19.42%
Gross Profit
-0.060.810.6414.623.91
Operating Income
-79.16-72.93-68.51-27.35-37.44-82.13
Net Income
-84.74-78.26-35.13-31.54-41.66-84.38
Earnings Per Share
-5.46-5.84-20.91-113.58-1063.00-
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
81.9998.34134.557.4213.1754.59
Total Debt
000019.4232.83
Net Cash (Debt)
81.9998.34134.557.42-6.2421.75
Net Cash Growth
-34.43%-26.91%1714.51%--14.97%
Net Cash Per Share
5.197.3417.9526.70-159.28-

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-59.69-51.46-49.06-30.68-26.75-70.89
Capital Expenditures
----0.16-0.1-0.11
Free Cash Flow
-59.69-51.46-49.06-30.84-26.85-71.01
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
-100.00%182.99%33.26%80.98%72.38%
Operating Margin
--123602.00%-15535.60%-1421.57%-207.41%-1521.56%
Pretax Margin
--132362.71%-7939.91%-1638.77%-230.62%-1566.23%
Profit Margin
--132642.00%-7965.76%-1639.50%-230.78%-1562.60%
FCF Margin
--87216.90%-11123.80%-1602.81%-148.72%-1315.39%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
16184.735698.16176.433.792.6335.52